浸入科技 IMMR 深 沪
已收盘 10-31 16:00:00 美东时间
6.69
+0.070
+1.06%
华盛通- 最 高6.75
- 今 开6.62
- 成交量 31.58万股
- 最 低 6.59
- 昨 收 6.62
- 总市值 2.17亿
- 52周最高 10.34
- 市盈率 静 6.41
- 换手率 0.97%
- 52周最低 6.335
- 委 比 66.08%
- 总股本 3239.64万
- 历史最高 16.925
- 量 比 0.82
- 振 幅 2.42%
- 历史最低 3.37
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
BWS Financial Maintains Buy on Immersion, Maintains $13.5 Price Target
BWS Financial analyst Hamed Khorsand maintains Immersion (NASDAQ:IMMR) with a Buy and maintains $13.5 price target.
10-15 22:25
Immersion Corporation receives Nasdaq notice for delayed filing
Immersion Corporation (NASDAQ:IMMR) received a Nasdaq delinquency notice for failing to timely file its report for the quarter ended July 31, 2025. The company is now non-compliant with Nasdaq’s conti...
10-03 04:15
Immersion Corp Recevies Delinquency Compliance Notice From Nasdaq
Immersion Corporation ("Immersion", the "Company", "we", "us" or "our") (NASDAQ:IMMR), a leading provider of technologies for haptics, announced that on September 29, 2025, it received a delinquency compliance alert
10-03 04:08
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Immuneering Corporation announced a proposed underwritten public offering of its Class A common stock or pre-funded warrants, alongside a private placement with Sanofi for $25 million. Proceeds will fund the advancement of preclinical and clinical development of product candidates and general corporate purposes. Leerink Partners and Oppenheimer & Co. Inc. are acting as joint bookrunners and placement agents. The offering is subject to market cond...
09-24 20:05
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
<p>Immuneering Corporation announced the appointment of Thomas J. Schall, Ph.D., as Chairman of its Board of Directors. Dr. Schall, a seasoned biotech executive and scientist with over 30 years of experience, is known for founding ChemoCentryx and leading the development of Tavneos, which was approved by the FDA and led to the company's acquisition by Amgen for nearly $4 billion. His expertise is expected to strengthen Immuneering's progress in a...
09-16 11:00
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
<p>Immuneering Corporation plans to announce updated overall survival data for first-line pancreatic cancer patients treated with atebimetinib + mGnP on September 25, 2025, during an investor call at 8 a.m. ET. The company will also present this data at the PanCAN Scientific Summit on September 28 and review preclinical data on Deep Cyclic Inhibitors at the RAS-Targeted Drug Development Summit on September 17. Ben Zeskind, CEO, highlighted the si...
09-10 11:00
Immersion Corp. Board Declares Prior Quarterly Financial Statements For 2024-2025 Non-Reliable Due To Barnes & Noble Education Sales And Cost Accounting Issues
On September 8, 2025, the Board of Directors (the "Board") of Immersion Corporation (the "Company") concluded that the Company's previously-issued unaudited interim condensed consolidated financial statements for the
09-09 20:57
Immuneering Announces Closing of $25 Million Private Placement
<p>Immuneering Corporation announced the closing of a $25 million private placement to institutional and accredited investors. Proceeds will support the development of its cancer treatments, including a Phase 2a trial for its lead candidate, atebimetinib. Leerink Partners acted as financial advisor.</p>
08-26 20:05
Immersion Faces Nasdaq Filing Compliance Deadline
The latest update is out from Immersion ( ($IMMR) ). On August 20, 2025, Immers...
08-23 04:48
